Form Type:  SC 13G/A
Filing Date:  2/14/2023 
CIK:  0001410098 
Address:  300 CONNELL DRIVE
SUITE 4200
City, State, Zip:  BERKELEY HEIGHTS, New Jersey 07922 
Telephone:  908-517-9500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.12 (2.52%)  
Trade Time: 
May 26  
Market Cap: 
Trade CRMD now with 

© 2023  
Description of Business
We are a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions. Our primary focus is on the development of our lead product candidate, DefenCath(TM), for potential commercialization in the United States, or U.S., and other key markets. We have in-licensed the worldwide rights to develop and commercialize DefenCath and Neutrolin®. The name DefenCath is the U.S. proprietary name conditionally approved by the U.S. Food and Drug Administration, or FDA, while the name Neutrolin was used in the European Union, or EU, and other territories where we received CE-Mark approval for the commercial distribution of Neutrolin as a catheter lock solution, or CLS, regulated as a medical device.
Register and access this filing in:     

EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.